Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™ ; results surpass current standards of care
Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company’s portfolio of transformational medicines ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO ™ beyond lung cancer
Monthly dosing reduces treatment visits while maintaining established safety and efficacy 1,2
Outcome marks the first of several trials scheduled for 2026
As the "sell America" trade has gained popularity, the launch of USMD is doubling down on "America First" tech trades. Here's what to know.
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END
Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28 th Annual Global Healthcare Conference on Tuesday, March 10 th , 2026. Management will participate in a Fireside...
Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.
OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse events i Additional data presented further reinforces...